CytoSorbents Corp (CTSO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$4.60+0.88%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · CTSO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 74.1% |
| Our one-year growth estimate | diamond | 14.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 59.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers
CTSO — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, CytoSorbents Corporation issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.*
Why it matters: Germany sales fell 24% in Q2, while other sales areas grew. New hires are meant to restore country coverage.
Supportive ifGermany sales rise year over year in a reported quarter. The company adds 3 to 5 sales reps by early 2027.
Worry ifGermany sales fall year over year again, or the company does not add 3 to 5 reps by early 2027.
Why it matters: The original FDA filing was denied, and a new filing needs added test data and patient evidence. A filing would mark progress, not approval.
Supportive ifBy early 2027, CytoSorbents submits a new De Novo application for DrugSorb-ATR. It adds test data and real-world patient evidence.
Worry ifThe new De Novo filing is delayed beyond early 2027, or FDA asks for more data before it can be filed.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$349 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $914 loss on $10,000 · 9.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,172 loss on $10,000 · 81.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.